Du är här

2015-10-07

Adaptimmune Therapeutics plc: Adaptimmune to Report Full Fiscal Year 2015 Financial Results on October 13, 2015

PHILADELPHIA, Pa. and OXFORD, UK, Oct. 07, 2015 (GLOBE NEWSWIRE) --
Adaptimmune Therapeutics plc (Nasdaq:ADAP), ("Adaptimmune" or the "Company"),
a clinical stage biopharmaceutical company focused on the use of T-cell
therapy to treat cancer, will announce financial results for its 2015 full
fiscal year ended June 30 before the open of the U.S. markets on Tuesday,
October 13, 2015. Following the announcement, the Company will host a live
teleconference and webcast at 8:00 a.m. Eastern Time (1:00 p.m. BST) on
Tuesday, October 13, 2015, at which time management will provide a business
update and discuss the 2015 full fiscal year financial results.

The press release and the live webcast of the conference call will be
available via Adaptimmune's corporate website at www.adaptimmune.com. The
webcast will be made available on the events page. An archive will be
available after the call at the same address.

To participate in the live conference call, if preferred, please dial (877)
280-1254 (U.S.) or +44 (0) 20 3427 1919 or 0800 279 4992 (United Kingdom).
After placing the call, please ask to be joined into the Adaptimmune
conference call and provide the confirmation code (7224348).

About Adaptimmune

Adaptimmune is a clinical stage biopharmaceutical company focused on novel
cancer immunotherapy products based on its T-cell receptor platform.
Established in 2008, the Company aims to utilize the body's own machinery -
the T-cell - to target and destroy cancer cells by using engineered,
increased affinity T-cell receptors (TCRs) as a means of strengthening
natural patient T-cell responses. Adaptimmune's lead program is an
affinity-enhanced TCR therapeutic targeting the NY-ESO cancer antigen. Its
NY-ESO TCR therapeutic candidate has demonstrated signs of efficacy and
tolerability in Phase 1/2 trials in solid tumors and in hematologic cancer
types, including synovial sarcoma and multiple myeloma. As of June 30, 2015,
85 patients had been treated with Adaptimmune's NY-ESO TCR therapeutic: 47
under Adaptimmune's IND, and 38 under a National Cancer Institute IND. In
June 2014, Adaptimmune announced that it had entered into a strategic
collaboration and licensing agreement with GlaxoSmithKline (GSK) for the
development and commercialization of the NY-ESO TCR program in partnership
with GSK. In addition, Adaptimmune has a number of proprietary programs and
its next TCR therapeutic candidate, directed at MAGE A-10, is scheduled to
enter the clinic in 2015. The Company has identified over 30 intracellular
target peptides preferentially expressed in cancer cells and is currently
progressing 12 of these through unpartnered research programs. Adaptimmune
has over 150 employees and is located in Oxfordshire, UK and Philadelphia,
USA. For more information: http://www.adaptimmune.com

Forward-Looking Statements

This press release contains "forward-looking statements," as that term is
defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),
which statements may be identified by words such as "believe," "may", "will,"
"estimate," "continue," "anticipate," "intend," "expect" and other words of
similar meaning.
These forward-looking statements involve certain risks and uncertainties. Such
risks and uncertainties could cause our actual results to differ materially
from those indicated by such forward-looking statements, and include, without
limitation: the success, cost and timing of our product development
activities and clinical trials; our ability to submit an IND and successfully
advance our technology platform to improve the safety and effectiveness of
our existing TCR therapeutic candidates; the rate and degree of market
acceptance of T-cell therapy generally and of our TCR therapeutic candidates;
government regulation and approval, including, but not limited to, the
expected regulatory approval timelines for TCR therapeutic candidates; and
our ability to protect our proprietary technology and enforce our
intellectual property rights; amongst others. For a further description of
the risks and uncertainties that could cause our actual results to differ
materially from those expressed in these forward-looking statements, as well
as risks relating to our business in general, we refer you to our Prospectus
filed with the Securities and Exchange Commission on May 7, 2015. We urge you
to consider these factors carefully in evaluating the forward-looking
statements herein and are cautioned not to place undue reliance on such
forward-looking statements, which are qualified in their entirety by this
cautionary statement. The forward-looking statements contained in this press
release speak only as of the date the statements were made and we do not
undertake any obligation to update such forward-looking statements to reflect
subsequent events or circumstances. We intend that all forward-looking
statements be subject to the safe-harbor provisions of the PSLRA.
Adaptimmune Contacts
Will Roberts
Vice President, Investor Relations
T: (215) 825-9306
E: will.roberts@adaptimmune.com

Margaret Henry
Head of PR
T: +44 (0)1235 430036
Mob: +44 (0)7710 304249
E: margaret.henry@adaptimmune.com

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Adaptimmune Therapeutics plc via Globenewswire

HUG#1957437

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.